A Phase 3 interventional study of Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine and Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine in Meningitis, Meningococcal Meningitis and Meningococcal Infections, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 33 sites in 4 countries. Open to participants aged 12 Months to 23 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-05.
Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Meningitis, Meningococcal by Sanofi — none open to participants now, none under way, none of them phase 3. Meningitis, Meningococcal · Sanofi.
Among the 24 studies in Meningitis, Meningococcal by Sanofi, this one is the 11th largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2017, is one of 13 in phase 3, and was the 18th registered.
125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.
Browse Meningitis, Meningococcal studies →None of the 24 studies in Meningitis, Meningococcal by Sanofi is open now. The open studies under Meningitis, Meningococcal, anywhere →
Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 12 Months to 23 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 13 · Phase 4 3
First in 2006; this study’s year is marked. 2 started in 2017.
This study's enrollment of 918 is above the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.
Median enrollment 907 across the 23 interventional studies, 100 across the 1 observational. Of the 24 that completed or were terminated, 22 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Sanofi Pasteur, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 24 studies in Meningitis, Meningococcal by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study was to evaluate the immunogenicity and describe the safety of a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine compared to the licensed Meningococcal polysaccharide groups A, C, W-135 and Y (Nimenrix®) Conjugate vaccine in toddlers 12 to 23 months of age in the European Union (EU). The toddlers were either meningococcal vaccine naïve or had received monovalent meningococcal C (MenC) vaccination during infancy to evaluate any potential impact of the meningococcal vaccine background on the immunogenicity and safety profile of the investigational product.
Primary Objectives:
Secondary Objectives:
Healthy toddlers were randomized depending on their meningococcal priming vaccination background (either meningococcal vaccine naïve or primed with MenC) and received a single dose of either MenACYW Conjugate vaccine or Nimenrix®. They were assessed for immunogenicity at baseline (pre-vaccination) and 30 to 44 days post-vaccination. Safety information were collected post-vaccination and throughout the entire study.
125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.
This study's enrollment of 918 is above the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.
Browse Meningitis, Meningococcal studies →Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
First submitted after Sanofi Pasteur became part of Sanofi.
Compared within Meningitis, Meningococcal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Meningitis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy, meningococcal vaccine naive toddlers aged 12 to 23 months received a single dose of MenACYW Conjugate vaccine on Day 0.
Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Healthy, meningococcal vaccine naive toddlers aged 12 to 23 months received a single dose of Nimenrix® vaccine on Day 0.
Biological: Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine
Healthy, meningococcal C vaccine primed toddlers aged 12 to 23 months received a single dose of MenACYW Conjugate vaccine on Day 0.
Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Healthy, meningococcal C vaccine primed toddlers aged 12 to 23 months received a single dose of Nimenrix® vaccine on Day 0.
Biological: Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine
0.5 milliliter (mL), Intramuscular
Also known as: MenACYW Conjugate vaccine
0.5 mL, Intramuscular
Also known as: Nimenrix®
0.5 mL, Intramuscular
Also known as: MenACYW Conjugate vaccine
0.5 mL, Intramuscular
Also known as: Nimenrix®
Percentage of Participants With Antibody Titers Greater Than or Equal to (>=) 1:8 Against Meningococcal Serogroups A, C, Y, and W in Toddlers Who Either Were Meningococcal Vaccine Naïve or Had Received Monovalent MenC Vaccination During Infancy
Antibody titers against Meningococcal Serogroups A, C, Y, and W were measured by serum bactericidal assay using human complement (hSBA). Data for this outcome measure were planned to be analyzed for the pooled population of MenACYW Conjugate vaccine and Nimenrix® reporting groups.
Time frame: Day 30 (post-vaccination)
Percentage of Participants With Antibody Titers >=1:8 Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine or Nimenrix® in Meningococcal Vaccine Naïve Toddlers
Antibody titers against Meningococcal Serogroups A, C, Y, and W were measured by hSBA.
Time frame: Day 30 (post-vaccination)
Geometric Mean Titers (GMTs) of Antibodies Against Meningococcal Serogroups A, C, Y, and W in Toddlers Who Either Were Meningococcal Vaccine Naïve or Had Received Monovalent MenC Vaccination During Infancy
Antibody titers against Meningococcal Serogroups A, C, Y, and W were measured by hSBA.
Time frame: Day 30 (post-vaccination)
Geometric Mean Titers of Antibodies Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine or Nimenrix® in Vaccine Naive Toddlers
Antibody titers against Meningococcal Serogroups A, C, Y, and W were measured by hSBA.
Time frame: Day 30 (post-vaccination)
Geometric Mean Titers of Antibodies Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With MenACYW Conjugate Vaccine or Nimenrix® in Toddlers Who Had Received Monovalent MenC Vaccination During Infancy
Antibody titers against Meningococcal Serogroups A, C, Y, and W were measured by hSBA.
Time frame: Day 30 (post-vaccination)
Study participants were enrolled in 34 centers in Spain, Hungary, Germany and Finland from 24 February 2017 to 21 September 2017.
| Milestone | Group 1(Meningococcal Vaccine-Naive):MenACYW Conjugate Vaccine | Group 2 (Meningococcal Vaccine-Naive): Nimenrix® | Group 3 (MenC-Primed) MenACYW Conjugate Vaccine | Group 4 (MenC-Primed): Nimenrix® |
|---|---|---|---|---|
| Started | 306 | 306 | 203 | 103 |
| Safety analysis set (safas) | 303 | 306 | 203 | 102 |
| Per protocol analysis set (ppas) | 293 | 296 | 198 | 99 |
| Completed | 303 | 303 | 203 | 101 |
| Not completed | 3 | 3 | 0 | 2 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 2 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
Antibody titers against Meningococcal Serogroups A, C, Y, and W were measured by serum bactericidal assay using human complement (hSBA). Data for this outcome measure were planned to be analyzed for the pooled population of MenACYW Conjugate vaccine and Nimenrix® reporting groups.
| percentage of participants | MenACYW Conjugate Vaccine (Groups 1 and 3) | Nimenrix® (Groups 2 and 4) |
|---|---|---|
| Serogroup A | 90.4 (87.4 to 92.9) | 91.6 (88.4 to 94.2) |
| Serogroup C | 99.2 (97.9 to 99.8) | 85.5 (81.7 to 88.9) |
| Serogroup Y | 94.3 (91.8 to 96.2) | 91.6 (88.5 to 94.2) |
| Serogroup W | 84.9 (81.4 to 87.9) | 84.0 (80.0 to 87.5) |
Antibody titers against Meningococcal Serogroups A, C, Y, and W were measured by hSBA.
| percentage of participants | Group 1(Meningococcal Vaccine-Naive):MenACYW Conjugate Vaccine | Group 2 (Meningococcal Vaccine-Naive): Nimenrix® |
|---|---|---|
| Serogroup A | 90.8 (86.9 to 93.8) | 89.5 (85.4 to 92.7) |
| Serogroup C | 99.3 (97.6 to 99.9) | 81.4 (76.4 to 85.6) |
| Serogroup Y | 93.2 (89.7 to 95.8) | 91.6 (87.8 to 94.5) |
| Serogroup W | 83.6 (78.9 to 87.7) | 83.4 (78.7 to 87.5) |
Antibody titers against Meningococcal Serogroups A, C, Y, and W were measured by hSBA.
| titers (1/dilution) | MenACYW Conjugate Vaccine (Groups 1 and 3) | Nimenrix® (Groups 2 and 4) |
|---|---|---|
| Serogroup A | 29.9 (26.9 to 33.2) | 34.5 (30.5 to 39.0) |
| Serogroup C | 880 (748 to 1035) | 77.1 (60.7 to 98.0) |
| Serogroup Y | 41.7 (37.5 to 46.5) | 31.9 (28.4 to 36.0) |
| Serogroup W | 24.4 (21.8 to 27.5) | 17.7 (15.8 to 19.8) |
Antibody titers against Meningococcal Serogroups A, C, Y, and W were measured by hSBA.
| titers (1/dilution) | Group 1(Meningococcal Vaccine-Naive):MenACYW Conjugate Vaccine | Group 2 (Meningococcal Vaccine-Naive): Nimenrix® |
|---|---|---|
| Serogroup A | 28.7 (25.2 to 32.6) | 28.0 (24.4 to 32.1) |
| Serogroup C | 436 (380 to 500) | 26.4 (22.5 to 31.0) |
| Serogroup Y | 38.0 (33.0 to 43.9) | 32.2 (28.0 to 37.0) |
| Serogroup W | 22.0 (18.9 to 25.5) | 16.4 (14.4 to 18.6) |
Antibody titers against Meningococcal Serogroups A, C, Y, and W were measured by hSBA.
| titers (1/dilution) | Group 3 (MenC-Primed): MenACYW Conjugate Vaccine | Group 4 (MenC-Primed): Nimenrix® |
|---|---|---|
| Serogroup A | 31.8 (26.5 to 38.1) | 64.0 (50.9 to 80.5) |
| Serogroup C | 2514 (1875 to 3372) | 1883 (1276 to 2779) |
| Serogroup Y | 48.0 (40.6 to 56.7) | 31.3 (24.8 to 39.5) |
| Serogroup W | 28.7 (23.8 to 34.5) | 22.3 (17.7 to 28.2) |
Collected over Adverse event (AE) data were collected from Day 0 (post-vaccination) up to 30 days after vaccination. Solicited Reactions (SRs) data were collected within 7 days after vaccination. Serious adverse events (SAEs) data were collected throughout the study (up to 30 days after vaccination).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1(Meningococcal Vaccine-Naive):MenACYW Conjugate Vaccine | 0/303 (0%) | 2/303 (0.7%) | 261/303 (86.1%) |
| Group 2 (Meningococcal Vaccine-Naive): Nimenrix® | 0/306 (0%) | 1/306 (0.3%) | 266/306 (86.9%) |
| Group 3 (MenC-Primed): MenACYW Conjugate Vaccine | 0/203 (0%) | 2/203 (1%) | 151/203 (74.4%) |
| Group 4 (MenC-Primed): Nimenrix® | 0/102 (0%) | 2/102 (2%) | 65/102 (63.7%) |
| Event | Group 1(Meningococcal Vaccine-Naive):MenACYW Conjugate Vaccine | Group 2 (Meningococcal Vaccine-Naive): Nimenrix® | Group 3 (MenC-Primed): MenACYW Conjugate Vaccine | Group 4 (MenC-Primed): Nimenrix® |
|---|---|---|---|---|
| BronchitisInfections and infestations | 0/303 | 0/306 | 0/203 | 1/102 |
| Blood Immunoglobulin A DecreasedInvestigations | 0/303 | 0/306 | 0/203 | 1/102 |
| BronchospasmRespiratory, thoracic and mediastinal disorders | 0/303 | 0/306 | 0/203 | 1/102 |
| Campylobacter GastroenteritisInfections and infestations | 0/303 | 0/306 | 1/203 | 0/102 |
| Craniocerebral InjuryInjury, poisoning and procedural complications | 0/303 | 0/306 | 1/203 | 0/102 |
| SeizureNervous system disorders | 0/303 | 0/306 | 1/203 | 0/102 |
| Haemolytic Uraemic SyndromeBlood and lymphatic system disorders | 1/303 | 0/306 | 0/203 | 0/102 |
| Intestinal MalrotationCongenital, familial and genetic disorders | 1/303 | 0/306 | 0/203 | 0/102 |
| Gastroenteritis Escherichia ColiInfections and infestations | 1/303 | 0/306 | 0/203 | 0/102 |
| Febrile ConvulsionNervous system disorders | 1/303 | 0/306 | 0/203 | 0/102 |
| Event | Group 1(Meningococcal Vaccine-Naive):MenACYW Conjugate Vaccine | Group 2 (Meningococcal Vaccine-Naive): Nimenrix® | Group 3 (MenC-Primed): MenACYW Conjugate Vaccine | Group 4 (MenC-Primed): Nimenrix® |
|---|---|---|---|---|
| IrritabilityPsychiatric disorders | 144/303 | 127/306 | 76/203 | 36/102 |
| Injection Site ErythemaGeneral disorders | 122/303 | 116/306 | 52/203 | 21/102 |
| Injection Site PainGeneral disorders | 122/303 | 113/306 | 55/203 | 20/102 |
| CryingGeneral disorders | 106/303 | 111/306 | 48/203 | 23/102 |
| Decreased AppetiteMetabolism and nutrition disorders | 91/303 | 94/306 | 56/203 | 28/102 |
| SomnolenceNervous system disorders | 64/303 | 55/306 | 51/203 | 19/102 |
| Injection Site SwellingGeneral disorders | 63/303 | 52/306 | 35/203 | 9/102 |
| Upper Respiratory Tract InfectionInfections and infestations | 49/303 | 39/306 | 14/203 | 7/102 |
| PyrexiaGeneral disorders | 40/303 | 48/306 | 29/203 | 14/102 |
| VomitingGastrointestinal disorders | 23/303 | 13/306 | 21/203 | 8/102 |
Analysis was performed on all randomized participants.
| Age, Continuous(months) | Group 1(Meningococcal Vaccine-Naive):MenACYW Conjugate Vaccine | Group 2 (Meningococcal Vaccine-Naive): Nimenrix® | Group 3 (MenC-Primed): MenACYW Conjugate Vaccine | Group 4 (MenC-Primed): Nimenrix® | Total |
|---|---|---|---|---|---|
| Mean | 16.1 ± 3.32 | 16.2 ± 3.19 | 14.0 ± 3.01 | 13.8 ± 2.72 | 15.4 ± 3.31 |
| Sex: Female, Male(Participants) | Group 1(Meningococcal Vaccine-Naive):MenACYW Conjugate Vaccine | Group 2 (Meningococcal Vaccine-Naive): Nimenrix® | Group 3 (MenC-Primed): MenACYW Conjugate Vaccine | Group 4 (MenC-Primed): Nimenrix® | Total |
|---|---|---|---|---|---|
| Female | 140 | 145 | 97 | 53 | 435 |
| Male | 166 | 161 | 106 | 50 | 483 |
| Race (NIH/OMB)(Participants) | Group 1(Meningococcal Vaccine-Naive):MenACYW Conjugate Vaccine | Group 2 (Meningococcal Vaccine-Naive): Nimenrix® | Group 3 (MenC-Primed): MenACYW Conjugate Vaccine | Group 4 (MenC-Primed): Nimenrix® | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 1 |
| Asian | 1 | 1 | 0 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 0 | 1 | 3 |
| White | 115 | 132 | 197 | 99 | 543 |
| More than one race | 2 | 3 | 5 | 2 | 12 |
| Unknown or Not Reported | 188 | 168 | 0 | 0 | 356 |
| Region of Enrollment(Participants) | Group 1(Meningococcal Vaccine-Naive):MenACYW Conjugate Vaccine | Group 2 (Meningococcal Vaccine-Naive): Nimenrix® | Group 3 (MenC-Primed): MenACYW Conjugate Vaccine | Group 4 (MenC-Primed): Nimenrix® | Total |
|---|---|---|---|---|---|
| Hungary | 0 | 0 | 95 | 50 | 145 |
| Finland | 188 | 168 | 0 | 0 | 356 |
| Germany | 118 | 138 | 0 | 0 | 256 |
| Spain | 0 | 0 | 108 | 53 | 161 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Feb 2017 to primary completion in Oct 2017, 8 months.
Results were first posted in Jun 2020, 2 years 7 months after primary completion. A results delay was requested in Oct 2018.
Of 25 phase 3 interventional studies under Meningitis, Meningococcal, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 20. This study's 8 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sanofi Pasteur, a Sanofi Company →